Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

bout Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is being evaluated in a Phase 1 study. We are currently evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Rigrodsky & Long, P.A.: , Do you, or ... AERI )? , Did you purchase your shares between August ... lose money in your investment in Aerie Pharmaceuticals, Inc.? , ... Rigrodsky & Long, P.A. , including former Special Assistant United ... has been filed in the United States District Court for the ...
(Date:5/6/2015)... , May 05, 2015 Research and ... the addition of the "Chromatography (Instruments and ... report to their offering. Chromatography is ... identifying the component of a complex mixture by ... the decades the scientists have considered chromatography as ...
(Date:5/6/2015)... YORK , May 6, 2015   CEFALY ... electrical nerve stimulation device specifically authorized for use prior ... announce significant breakthroughs in migraine treatment at the EUROHEADPAIN ... in Valencia, Spain , from May ... at a meeting of EUROHEADPAIN, a major European research ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3Global Chromatography (Instruments and Reagents) Market 2015 - Forecasts to 2019 2CEFALY to Present Breakthrough Data in Migraine Treatment at International Headache Society Congress 2
... Inc., the largest,privately held spinal implant manufacturer in ... Spacers have been implanted under an,Investigational Device Exemption ... II and Dr. Rhett Murray., The FLEXUS(TM) ... two,spinous processes with minimal disruption to the surrounding ...
... (BiTE) showing clinical benefit in cancer,patients; Blinatumomab enables patients own T ... ... cancer cells, BETHESDA, Md., Aug. 14 Micromet, Inc.,(Nasdaq: ... treatment of cancer, inflammation and autoimmune,diseases, today announced publication of a ...
Cached Medicine Technology:First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6
(Date:5/6/2015)... Illinois (PRWEB) May 06, 2015 RPS Revolution ... take on the tried and true Rock Paper Scissors game ... With fun characters that encourage storytelling and easy to learn ... new twist on an old favorite. RPS Revolution ... it into whimsical characters that are grouped in set of ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Imprivata ... announced that CTO David Ting will lead a discussion ... associated data security and user authentication challenges, during ... The session will focus on the benefits of creating ... which care providers and patients can share information. It ...
(Date:5/6/2015)... 06, 2015 Qushanna Doby (20) was arrested ... drug treatment center in Florida while under the influence of ... New surveillance tapes released by CBS4’s Peter D’Oench records Doby ... Doby’s child is around one year old. The drug treatment ... outside was not named. The residents polled by CBS Miami ...
(Date:5/6/2015)... The Canton Group is joining Lardarius Webb ... annual charity softball game. The event takes place on Friday, ... Past years guests include Joe Flacco, John Harbaugh, Ed Reed ... sale if you are interested in attending. , The ... as SOAR Baltimore and The CollegeBound Foundation ...
(Date:5/6/2015)... May 06, 2015 TMG Health, the ... the Medicare Advantage, Medicare Part D and Managed Medicaid ... and Resilience Team category at the BCI North America ... to recognize the outstanding contribution of business continuity professionals ... America Region, including the USA and Canada. The North ...
Breaking Medicine News(10 mins):Health News:RPS Revolution Launches Kickstarter Campaign 2Health News:RPS Revolution Launches Kickstarter Campaign 3Health News:Imprivata to Lead Discussion about Patient and Provider Authentication Challenges and the Internet of Things in Healthcare during Citrix Synergy 2Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , NASHVILLE, Tenn., Sept. 9 ... provider of revenue and payment cycle management solutions, today ... Healthcare Network Accreditation Program (HNAP) from the Electronic Healthcare ... in health data processing and transactions and indicates compliance ...
... STOCKHOLM, September 9 Karolinska Development ... that will commercialize its,dermatology and wound healing opportunities as ... all of its,holdings from its five dermatology and wound ... company. , "This is a ...
... New Hearing ... ... website www.AdviceOnHearingAids.com is proving to be a valuable and informative resource for consumers ... aids, and so many different brands, styles, types of technology, and opinions about which one ...
... , TITUSVILLE, N.J., Sept. 9 Attention ... percent of children(1) and 4 percent of adults in the U.S.(2) ... 20 percent of U.S. school-aged children meet the Diagnostic and Statistical ... receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 ...
... , , , HERMOSA ... empower parents across the globe to participate in the fight against AIDS ... ... go outside, go discover, go experience. Through the new partnership with ... to not only improve their own lives, but also the lives of ...
Cached Medicine News:Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 2Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 3Health News:Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio 2Health News:Help for Hearing Loss - Now Available Online 2Health News:Help for Hearing Loss - Now Available Online 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 2Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 3Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 4
... to the National Academy of ... use of cardiac markers in ... is definitive of acute myocardial ... assay was designed for rapid ...
A fluorogenic enzyme-linked immunoassay (ELISA) for the quantitative measurement of myoglobin in human serum or plasma aiding in the diagnosis of acute myocardial infarction (AMI). Features : Dry che...
Clinical marker immunoassay kit for detection of Myoglobin....
AxSYM Myoglobin is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of myoglobin in human serum or plasma on the AxSYM System....
Medicine Products: